TICKERNERD
Menu
MCRBMCRBHealthcare · Biotechnology

MCRB Stock Forecast: Seres Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$1.79
−0.56% on the day

The 2 Wall Street analysts covering Seres Therapeutics, Inc. hold a median 12-month price target of $17 — +849.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 27 Oct 2026 — in the upper half.

Market cap
$19.9M
Ticker Nerd rank
55/ 100
Median analyst target
$17
Analysts covering
2
Revenue$736K
Operating income−$15.5M
Net income$4.6M
Free cash flow−$22.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−22.2%
1M
−49.1%
YTD
−88.0%
1Y
−89.6%
From 52W high
−93.7%
From 52W low
0.0%
$2
$29
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MCRB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Seres Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 27 Oct 2026
55/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
88
Revisions
79
Issuance
74
Volatility
71
Quality
51
Accruals
50
Growth
44
Value
18
Momentum
4

Size (88): Smaller than most of the companies we track.

Momentum (4): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MCRB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MCRB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25Jan 26Apr 26Jul 26Oct 26MCRBHigh $22Median $17Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $12Median $17High $22

The green dot is the last close — the median target sits +849.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 June 2026HC Wainwright & Co.InitiatesBuy$12
13 Mar 2026Canaccord GenuityMaintainsBuy—
24 Sept 2025Canaccord GenuityMaintainsBuy—
8 May 2025Chardan CapitalDowngradeNeutral—
20 Mar 2025Chardan CapitalMaintainsBuy—
14 Mar 2025Goldman SachsMaintainsSell—
14 Nov 2024Canaccord GenuityMaintainsBuy—
13 Nov 2024Chardan CapitalMaintainsBuy—
24 Oct 2024JP MorganDowngradeUnderweight—
13 Sept 2024Canaccord GenuityMaintainsBuy—
14 Aug 2024Canaccord GenuityMaintainsBuy—
14 Aug 2024Chardan CapitalMaintainsBuy—
7 June 2024Canaccord GenuityMaintainsBuy—
7 June 2024OppenheimerDowngradePerform—
9 May 2024OppenheimerMaintainsOutperform—
8 May 2024Chardan CapitalMaintainsBuy—
6 Mar 2024Chardan CapitalMaintainsBuy—
6 Mar 2024OppenheimerMaintainsOutperform—
16 Jan 2024OppenheimerMaintainsOutperform—
3 Nov 2023Goldman SachsMaintainsSell—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

MCRB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MCRB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, Seres Therapeutics, Inc. returned −89.6% against +13.6% for the S&P 500, dividends included.

MCRB vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26MCRBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MCRB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Seres Therapeutics, Inc. (MCRB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
11.7×

Cheaper than 53% of US stocks

Price / sales
9.6×

Cheaper than 14% of US stocks

Price / book
0.5×

Cheaper than 82% of US stocks

EV / EBITDA
−0.8×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
105.6%

Higher than 92% of US stocks

Earnings growth (YoY)
—
Gross margin
100.0%

Higher than 99% of US stocks

Operating margin
−2101.4%

Higher than 4% of US stocks

Net margin
−729.4%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−66.6%

Higher than 18% of US stocks

Return on assets
−39.8%

Higher than 10% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Seres Therapeutics, Inc. (MCRB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Seres Therapeutics, Inc. has a market value of $19.9M and an enterprise value of $60.7M.

  • Revenue in the twelve months to 30 June 2026: $1.9M. The latest quarter grew 105.6% year on year.

  • Net income over the same four quarters: −$22.5M, a −1192.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$51.3M.

  • Shares outstanding: 9.8M.

  • Trailing P/E: 11.7×; forward P/E: −0.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Seres Therapeutics, Inc. employs 66 people — $29K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 27 Oct 2026

Data provided by Twelve Data

Peers

MCRB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MCRBSeres Therapeutics, Inc.$19.9M55
JSPRJasper Therapeutics, Inc.$17.3M42
KYNBKyntra Bio, Inc.$18.2M43
NEUPNeuphoria Therapeutics, Inc.$18.2M8
QNTMQuantum BioPharma Ltd.$18.8M47
MRKRMarker Therapeutics, Inc.$15.9M64
COCPCocrystal Pharma, Inc.$18.9M58

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Seres Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MCRB news & analysis

Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026

GlobeNewsWire · 15 Oct 2026positive

Seres Therapeutics plans to present preclinical data for SER-428, an investigational live biotherapeutic designed to reduce bloodstream-infection risk in critically ill patients, at IDWeek 2026. The company says its novel oral liquid formulation is intended for patients unable to take capsules, including those receiving nutrition through a feeding tube.

Why it matters — The planned presentation provides MCRB watchers an update on SER-428 and its formulation for critically ill patients who cannot take oral capsules.

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 8 Sept 2026neutral

On September 4, 2026, Seres Therapeutics' Compensation and Talent Committee granted inducement stock options for an aggregate of 4,200 shares of common stock to two new employees under the company's 2022 Employment Inducement Award Plan, per Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $5.72 and vest over a four-year schedule tied to employment anniversary and quarterly service milestones.

Why it matters — This disclosure concerns new equity incentives granted to two incoming employees, a routine corporate-governance matter that MCRB watchers may track for insider-compensation and stock-issuance activity.

Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 1 Sept 2026neutral

Seres Therapeutics announced that management will attend the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY, and will present a company overview at 2 p.m. ET on September 15, 2026.

Why it matters — The scheduled company presentation at a major investment conference gives MCRB watchers an opportunity to hear management's current outlook and potentially gauge investor interest in the company.

Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs

GlobeNewsWire · 5 Aug 2026neutral

Seres Therapeutics reported its second quarter 2026 financial results and provided business updates. The company announced that 80% of SER-155 recipients achieved immunosuppressive-free clinical response at day 15 for immune checkpoint inhibitor-related enterocolitis in an investigator-sponsored trial, and it is engaging potential partners and seeking capital to advance its SER-155 programs. Seres also agreed to exit additional leased space early to further reduce ongoing facility-related cash costs.

Why it matters — MCRB watchers would care because SER-155's promising irEC data, ongoing partnership and capital-raising efforts, and further facility cost reductions are central to the company's strategy and financial trajectory.

FAQ

Frequently asked questions about MCRB stock

What is the MCRB stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Seres Therapeutics, Inc. have a median 12-month price target of $17, with estimates ranging from $12 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MCRB stock a buy right now?

Of the 2 analysts covering Seres Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Seres Therapeutics, Inc. 55 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MCRB?

As at 27 Oct 2026, Seres Therapeutics, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (88 of 100).

Will MCRB stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +849.7% from the last close, and Ticker Nerd's factor model ranks Seres Therapeutics, Inc. 55 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MCRB stock forecast for 2030?

No analyst covering Seres Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MCRB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $22 over the next 12 months.

How has MCRB stock performed over the past year?

Seres Therapeutics, Inc. returned -89.6% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Seres Therapeutics, Inc. do?

Seres Therapeutics Inc. is a clinical-stage biotechnology company focused on developing live biotherapeutics that modulate the human microbiome.

What is the latest news on MCRB?

The most recent item we track (GlobeNewsWire, 15 Oct 2026): "Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026". Seres Therapeutics plans to present preclinical data for SER-428, an investigational live biotherapeutic designed to reduce bloodstream-infection risk in critically ill patients, at IDWeek 2026. The company says its novel oral liquid formulation is intended for patients unable to take capsules, including those receiving nutrition through a feeding tube.

Company

About Seres Therapeutics, Inc.

Seres Therapeutics Inc. is a clinical-stage biotechnology company focused on developing live biotherapeutics that modulate the human microbiome. The company’s current portfolio centers on oral microbiome-based therapies designed to address serious diseases in areas such as gastrointestinal disorders, immune-mediated conditions, and infection prevention. Its pipeline includes investigational programs aimed at restoring healthy microbial balance and improving disease-relevant functions in the gut. Seres Therapeutics serves a specialized role in the biopharmaceutical market by advancing novel treatments for medically vulnerable patient populations, with development efforts centered on microbiome therapeutics rather than traditional small-molecule or antibody drugs. Headquartered in Cambridge, Massachusetts, Seres Therapeutics is positioned within the broader biotechnology sector as a developer of targeted live biotherapeutic products.

CEO Mr. Richard N. Kender B.S., M.B.A. · 66 employees · United States · https://www.serestherapeutics.com